Fig. 1

Quizartinib and pexidartinib are effective inhibitors of FLT-dependent AML cell lines. The viabilities (normalised with respect to control, i.e., 0.25% DMSO) of MOLM-14 (a, c) and MV4-11 (b, d) are shown as the cells are treated by increasing concentrations of quizartinib (a, b) and pexidartinib (c, d). Each measurement was carried out in triplicate after 48 h of growth in presence of an inhibitor in a given concentration. Cell viabilities are estimated from an MTS assay (see “Methods” section for details)